Lisa M D Archibald,Joseph B Orange,Donald J Jamieson
Lisa M D Archibald
A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive compu...
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis [0.03%]
治疗复发型多发性硬化症的长期达利珠单抗疗法
Monica A Rojas,Noel G Carlson,Thomas L Miller et al.
Monica A Rojas et al.
We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with dac...
Michael Harzheim,Bernd Sommer,Dieter Pöhlau
Michael Harzheim
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications [0.03%]
视神经脊髓炎中的抗水通道蛋白-4抗体的治疗意义
Romain Marignier,Pascale Giraudon,Sandra Vukusic et al.
Romain Marignier et al.
Devic's neuromyelitis optica (DNMO) is a demyelinating and inflammatory disease of the central nervous system (CNS) essentially restricted to the spinal cord and the optic nerves. It is a rare disorder with a prevalence estimated at less th...
An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions [0.03%]
.sydenham舞蹈病治疗进展：既往和当前干预措施的循证研究
Kathleen G Walker,Jo M Wilmshurst
Kathleen G Walker
Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune con...
E Ann Yeh,Bianca Weinstock-Guttman
E Ann Yeh
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested ...
Bernd C Kieseier,Douglas R Jeffery
Bernd C Kieseier
The likely pathogenic mechanisms of multiple sclerosis (MS) provide a sound rationale for investigating the efficacy of drugs possessing immunosuppressive or immunomodulatory properties. With proven efficacy, safety and tolerability, interf...
The use of gabapentin enacarbil in the treatment of restless legs syndrome [0.03%]
加巴喷丁恩卡比林治疗不安腿综合征的作用
Toby C Yaltho,William G Ondo
Toby C Yaltho
Restless legs syndrome (RLS) is a common sleep-related neurological disorder that is characterized by the urge to move, worsening at rest, improvement with activity, and worsening in the evening and night. Dopamine agonists are usually the ...
Olivier Flabeau,Wassilios G Meissner,François Tison
Olivier Flabeau
Multiple system atrophy (MSA) is a rare neurodegenerative disorder without any effective treatment in slowing or stopping disease progression. It is characterized by poor levodopa responsive Parkinsonism, cerebellar ataxia, pyramidal signs ...
Anna Serafini,Simone Lorenzut,Gian Luigi Gigli et al.
Anna Serafini et al.
Restless legs syndrome (RLS) is a neurological disorder characterized by an urge to move the legs often accompanied by unpleasant sensations. Symptoms appear during periods of rest or inactivity, particularly in the evening and at night, an...